Anti-TB therapy following drug-induced liver injury (TB-DILI)
Phase 4
- Conditions
- Drug induced liver injury in patients receiving tuberculosis treatment.Respiratory
- Registration Number
- ISRCTN92067975
- Lead Sponsor
- ottingham Clinical Trials Unit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 350
Inclusion Criteria
1. Aged =18 years
2. Experienced DILI with standard 4-drug ATT for active pulmonary or extra-pulmonary TB
3. Medically suitable
4. for re-introduction of standard 4-drug ATT
Exclusion Criteria
1. Requirement for alternative ATT
2. Unable to provide written informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method